Blocking mTOR signalling with rapamycin ameliorates imiquimod-induced psoriasis in mice

  • The mTOR (mechanistic target of rapamycin) inhibitor rapamycin has long been known for its immune suppressive properties, but it has shown limited therapeutic success when given systemically to patients with psoriasis. Recent data have shown that the mTOR pathway is hyperactivated in lesional psoriatic skin, which probably contributes to the disease by interfering with maturation of keratinocytes. This study investigated the effect of topical rapamycin treatment in an imiquimod-induced psoriatic mouse model. The disease was less severe if the mice had received rapamycin treatment. Immunohistological analysis revealed that rapamycin not only prevented the activation of mTOR signalling (P-mTOR and P-S6 levels), but almost normalized the expression of epidermal differentiation markers. In addition, the influx of innate immune cells into the draining lymph nodes was partially reduced by rapamycin treatment. These data emphasize the role of mTOR signalling in the pathogenesis of psoriasis, and support the investigation of topical mTOR inhibition as a novel anti-psoriatic strategy.

Download full text files

Export metadata

Author:Claudia BürgerGND, Nitesh Shirsath, Victoria Lang, Sandra Diehl, Roland KaufmannGND, Andreas WeigertORCiDGND, Ying-ying Han, Christian Ringel, Peter Wolf
Pubmed Id:
Parent Title (English):Acta dermato-venereologica
Publisher:Acta Dermato-Venereologica
Place of publication:Uppsala
Document Type:Article
Year of Completion:2017
Date of first Publication:2017/06/09
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2018/01/02
Tag:imiquimod; mTORC; psoriasis; rapamycin
Page Number:8
First Page:1087
Last Page:1094
This is an open access article under the CC BY-NC license
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Licence (English):License LogoCreative Commons - Namensnennung-Nicht kommerziell 4.0